1887

Abstract

Surmmary

The total and subclass antibody responses of mice and protection of these animals against live influenza A/Sichuan/2/87 virus challenge infection were determined after immunisation with homologous A/Sichuan/87 aqueous or ISCOM-formulated surface glycoprotein subunit antigens administered by either the oral or intramuscular routes. The results show that the greatest systemic and local antibody responses were elicited in mice immunised with A/Sichuan ISCOMs by the intramuscular route; protection against homologous virus challenge was also effective in these animals, particularly after two doses of the vaccine. However, relatively high immune responses and protection were also elicited by the A/Sichuan/87 ISCOM vaccine administered orally. Immunisation of mice by the intramuscular route resulted in levels of serum IgG2a subclass antibody significantly greater than those induced by the same preparation given by the oral route, or by the aqueous A/Sichuan/87 subunit antigen preparation administered by either route. The findings indicate that the ISCOM delivery system can be used for immunisation by the oral route, although in mice, under the conditions used, this strategy compares unfavourably with the intramuscular route in terms of both local and systemic immune responses and protection against homologous challenge virus infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-42-1-53
1995-01-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/42/1/medmicro-42-1-53.html?itemId=/content/journal/jmm/10.1099/00222615-42-1-53&mimeType=html&fmt=ahah

References

  1. Potter C. W., Oxford J. S. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69–75
    [Google Scholar]
  2. Potter C. W. Inactivated influenza virus vaccine. In Beare A. S. (ed) Basic and applied influenza research Boca Raton: Florida, CRC Press; 1982119
    [Google Scholar]
  3. Oxford J. S., Corcoran T., Knott R. Serological studies with influenza A (H1N1) viruses cultivated in eggs or canine kidney cell line (MDCK). Bull World Health Organ 1987; 65:181–187
    [Google Scholar]
  4. Schild G. C., Oxford J. S., de Jong J. C., Webster R. G. Evidence for host cell selection of influenza virus antigenic variants. Nature 1983; 303:706–709
    [Google Scholar]
  5. Robertson J. S. Studies on influenza virus in clinical material. Rev Med Virol 1993 (in press)
    [Google Scholar]
  6. Murphy B. R., Clements M. L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989; 146:107–116
    [Google Scholar]
  7. Waldman R. H., Ganguly R. Immunity to infections on secretory surfaces. J Infect Dis 1974; 130:419–440
    [Google Scholar]
  8. Farag-Mahmod F. I., Wyde P. R., Rosborough J. P., Six H. R. Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine 1988; 6:262–268
    [Google Scholar]
  9. Lazzell V., Waldman R. H., Rose C., Khakoo R., Jacknowitz A., Howard S. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine. J Biol Stand 1984; 12:315–321
    [Google Scholar]
  10. Potter C. W., Jennings R. The hamster as a model system for the study of influenza vaccines. Postgrad Med J 1976; 52:345–351
    [Google Scholar]
  11. Bomford R. Adjuvants for viral vaccines. Rev Med Virol 1992; 2:169–174
    [Google Scholar]
  12. Erturk M., Phillpotts R. J., Welch M. J., Jennings R. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine 1991; 9:728–734
    [Google Scholar]
  13. Morein B., Sundquist B., Hoglund S., Dalgaard K., Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457–460
    [Google Scholar]
  14. Morein B., Lovgren K., Hoglund S., Sundquist B. The ISCOM: an immunostimulating complex. Immunol Today 1987; 8:333–338
    [Google Scholar]
  15. Morgan A. J., Finerty S., Lovgren K., Scullion F. T., Morein B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol 1988; 69:2093–2096
    [Google Scholar]
  16. Osterhaus A., Weijer K., Uytdehaag F. Serological responses in cats vaccinated with FeL V ISCOM and an inactivated FeL V vaccine. Vaccine 1989; 7:137–141
    [Google Scholar]
  17. Ben Ahmeida E. T. S., Jennings R., Erturk M., Potter C. W. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMs, with FCA, ALH or as infectious virus. Arch Virol 1992; 125:71–86
    [Google Scholar]
  18. Lövgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 1988; 27:241–245
    [Google Scholar]
  19. Mowat A. M., Donachie A. M., Reid G., Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72:317–322
    [Google Scholar]
  20. Jones P. D., Tha-Hla R., Morein B., Lovgren K., Ada G. L. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (ISCOMs). Scand J Immunol 1988; 27:645–652
    [Google Scholar]
  21. Lövgren K., Kåberg H., Morein B. An experimental influenza subunit vaccine (ISCOM): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 1990; 82:435–439
    [Google Scholar]
  22. Mowat A. Mcl, Donachie A. M. ISCOMs—a novel strategy for mucosal immunization?. Immunol Today 1991; 12:383–385
    [Google Scholar]
  23. Hocart M. J., Mackenzie J. S., Stewart G. A. Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A. J Med Virol 1990; 30:92–96
    [Google Scholar]
  24. Tao S. J., Yang D. R., Guo D. Treatment of experimental influenza viral infection with monoclonal antibody against H3N2 influenza virus. Virus Inform Exchange Newsletter 1987; 4:15
    [Google Scholar]
  25. Jennings R., Denton M. D., Potter C. W. The hamster as an experimental animal for the study of influenza. I. The role of antibody in protection. Med Microbiol Immunol 1976; 162:217–226
    [Google Scholar]
  26. Crawford C. R., Mukhlis F. A., Jennings R., Oxford J. S., Hockley D. J., Potter C. W. Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions. Vaccine 1984; 2:193–198
    [Google Scholar]
  27. Jennings R., Qasim T., Sharrard R. M., Hockley D., Potter C. W. Zwitterionic detergent solubilisation of HSV-1 surface antigens. Arch Virol 1988; 98:137–153
    [Google Scholar]
  28. De Vries P., Van Binnendijk R. S., Van der Marel P. Measles virus fusion protein presented in an immune-stimulating complex (ISCOM) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus specific T cells and protection in mice. J Gen Virol 1988; 69:549–559
    [Google Scholar]
  29. Wood J. M., Schild G. C., Newman R. W., Seagroatt V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Dev Biol Stand 1977; 39:193–200
    [Google Scholar]
  30. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976; 72:248–254
    [Google Scholar]
  31. Jennings R., Smith T., Potter C. W. Use of enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study. Med Microbiol Immunol 1981; 169:247–258
    [Google Scholar]
  32. Thomas H. I. J., Morgan-Capner P. Specific IgG subclass antibody in rubella virus infection. Epidemiol Infect 1988; 100:443–454
    [Google Scholar]
  33. Phillips N. C., Emili A. Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production. Vaccine 1992; 10:151–158
    [Google Scholar]
  34. Ben-Ahmeida T., Smith T., Hicks D. A., Kinghorn G. R., Potter C. W. Incidence of Chlamydia antibody in patient groups, as measured by the ELISA technique. Int J STD AIDS 1990; 1:114–121
    [Google Scholar]
  35. Meurman O., Hanninen P., Krishna R. V., Ziegler T. Deter mination of IgG-and IgM-class antibodies to mumps virus by solid-phase enzyme immunoassay. J Virol Methods 1982; 4:249–256
    [Google Scholar]
  36. Erturk M., Hill T. J., Shimeld C., Jennings R. Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine. Arch Virol 1992; 125:87–101
    [Google Scholar]
  37. Steward M. W., Partidos C. D., D’Mello F., Howard C. R. Specificity of antibodies reactive with hepatitis B surface antigen following immunization with synthetic peptides. Vaccine 1993; 11:1405–1414
    [Google Scholar]
  38. Romanova J. R., Ermachenko T. A., Alexandrova G. I. Tannock GA. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine 1994; 12:23–27
    [Google Scholar]
  39. Smith T. L., Jennings R. Specificity and in vitro transfer of the immunosuppressive effect of detergent-disrupted influenza virus vaccine. Clin Exp Immunol 1990; 79:87–94
    [Google Scholar]
  40. Sundquist B., Lovgren K., Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine 1988; 6:49–53
    [Google Scholar]
  41. Browning M., Reid G., Osborne R., Jarrett O. Incorporation of soluble antigens into ISCOMs: HIV gp 120 ISCOMs induce virus neutralizing antibodies. Vaccine 1992; 10:585–590
    [Google Scholar]
  42. Heeg K., Kuon W., Wagner H. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol 1991; 21:1523–1527
    [Google Scholar]
  43. Coutelier J. P., Van der Logt J. P. M., Heesen F. W. A., Warnier G., Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165:64–69
    [Google Scholar]
  44. Balkovic E. S., Flovack J. A., Six H. R. Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different forms. Antiviral Res 1987; 8:151–160
    [Google Scholar]
  45. Takahashi H., Takeshita T., Morein B., Putney S., Germain R. N., Berzofsky J. A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990; 344:873–875
    [Google Scholar]
  46. Ben Ahmeida E. T. S., Gregoriadis G., Potter C. W., Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993; 11:1302–1309
    [Google Scholar]
  47. Potter C. W. Vaccination of infants and children: conclusions and recommendation. In Hannoun C., Kendal A. P., Klerk H.-D., Reuben F. L. (eds) Options for the control of Influenza II. Excerpta Medica 1993449–453
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-42-1-53
Loading
/content/journal/jmm/10.1099/00222615-42-1-53
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error